On the semiclassical description of N‐level systems interacting with radiation fields von Raggio, G. A., Zivi, H. S.

Volltext

Complete dynamics of a two-level quantum system in interaction with a radiation field von Zivi, H.S., Bauder, A., Günthard, Hs.H.

Volltext

Microwave spectroscopy of supersonic molecular beams: Single- and double-resonance experiments with OCS and HCCCN von Zivi, H.S., Bauder, A., H. Günthard, Hs

Volltext

Microwave stark spectroscopy of continuous supersonic molecular beams: OCS in pure and in Ar- and He-seeded beams von Zivi, H.S., Bauder, A., Günthard, Hs.H.

Volltext

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? von Mezynski, J., Pezaro, C., Bianchini, D., Zivi, A., Sandhu, S., Thompson, E., Hunt, J., Sheridan, E., Baikady, B., Sarvadikar, A., Maier, G., Reid, A.H.M., Mulick Cassidy, A., Olmos, D., Attard, G., de Bono, J.

Volltext

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy von Scher, Howard I, Fizazi, Karim, Saad, Fred, Taplin, Mary-Ellen, Sternberg, Cora N, Miller, Kurt, de Wit, Ronald, Mulders, Peter, Chi, Kim N, Shore, Neal D, Armstrong, Andrew J, Flaig, Thomas W, Fléchon, Aude, Mainwaring, Paul, Fleming, Mark, Hainsworth, John D, Hirmand, Mohammad, Selby, Bryan, Seely, Lynn, de Bono, Johann S

Volltext

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate can... von Bianchini, D, Omlin, A, Pezaro, C, Lorente, D, Ferraldeschi, R, Mukherji, D, Crespo, M, Figueiredo, I, Miranda, S, Riisnaes, R, Zivi, A, Buchbinder, A, Rathkopf, D E, Attard, G, Scher, H I, de Bono, J, Danila, D C

Volltext

Estimating Regions of Asymptotic Stability of Power Electronics Systems Using Genetic Algorithms von Loop, Benjamin P, Sudhoff, Scott D, Żak, Stanislaw H, Zivi, Edwin L

Volltext

Abiraterone and Increased Survival in Metastatic Prostate Cancer von de Bono, Johann S, Logothetis, Christopher J, Molina, Arturo, Fizazi, Karim, North, Scott, Chu, Luis, Chi, Kim N, Jones, Robert J, Goodman, Oscar B, Saad, Fred, Staffurth, John N, Mainwaring, Paul, Harland, Stephen, Flaig, Thomas W, Hutson, Thomas E, Cheng, Tina, Patterson, Helen, Hainsworth, John D, Ryan, Charles J, Sternberg, Cora N, Ellard, Susan L, Fléchon, Aude, Saleh, Mansoor, Scholz, Mark, Efstathiou, Eleni, Zivi, Andrea, Bianchini, Diletta, Loriot, Yohann, Chieffo, Nicole, Kheoh, Thian, Haqq, Christopher M, Scher, Howard I

Volltext

Phase I trial outcomes in older patients with advanced solid tumours von Khan, K H, Yap, T A, Ring, A, Molife, L R, Bodla, S, Thomas, K, Zivi, A, Smith, A, Judson, I, Banerji, U, de Bono, J S, Kaye, S B

Volltext

Platinum-based therapy in men with metastatic castration resistant prostate (mCRPC) with or without DNA repair defects: A multicentre retrospective analysis von Gillessen, S., Schmid, S., Beltran, H., Almeida, D.V.P., Mehra, N., Lavaud, P., Morales Barrera, R., Pignataro, D., Castro Marcos, E., Conteduca, V., Efstathiou, E., Le, H.M.L., Pezaro, C.V., Suzuki, H., Zivi, A., Klingbiel, D., Omlin, A.G.

Volltext

AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies von Omlin, A., Jones, R. J., van der Noll, R., Satoh, T., Niwakawa, M., Smith, S. A., Graham, J., Ong, M., Finkelman, R. D., Schellens, J. H. M., Zivi, A., Crespo, M., Riisnaes, R., Nava-Rodrigues, D., Malone, M. D., Dive, C., Sloane, R., Moore, D., Alumkal, J. J., Dymond, A., Dickinson, P. A., Ranson, M., Clack, G., de Bono, J., Elliott, T.

Volltext

Amplification-free detection of circulating microRNA biomarkers from body fluids based on fluorogenic oligonucleotide-templated reaction between engineered peptide nucleic acid pro... von Metcalf, GAD, Shibakawa, A, Patel, H, Sita-Lumsden, A, Zivi, A, Rama, N, Bevan, C, Ladame, S

Volltext

814PPlatinum-based therapy in men with metastatic castration resistant prostate (mCRPC) with or without DNA repair defects: A multicentre retrospective analysis von Gillessen, S, Schmid, S, Beltran, H, Almeida, D V P, Mehra, N, Lavaud, P, Morales Barrera, R, Pignataro, D, Castro Marcos, E, Conteduca, V, Efstathiou, E, Le, H M L, Pezaro, C V, Suzuki, H, Zivi, A, Klingbiel, D, Omlin, A G

Volltext

A first-in-human study of the oral selective androgen receptor down-regulating drug (SARD) AZD3514 in patients with castration-resistant prostate cancer (CRPC) von Omlin, Aurelius Gabriel, Jones, Robert J., van der Noll, Ruud, Graham, Janet, Ong, Michael, Finkelman, Richard D., Schellens, Jan HM, Zivi, Andrea, Crespo, Mateus, Clack, Glen, Alumkal, Joshi J., Dymond, Angela, Dickinson, Andrew, Ranson, Malcolm, Malone, Michael D, De Bono, Johann Sebastian, Elliott, Tony

Volltext

AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer - Results of two parallel first-in-human phase I studies von Omlin, A, Jones, R. J, Van Der Noll, R, Satoh, T, Niwakawa, M, Smith, S. A, Graham, J, Ong, M, Finkelman, R. D, Schellens, J. H M, Zivi, A, Crespo, M, Riisnaes, R, Nava-Rodrigues, D, Malone, M. D, Dive, C, Sloane, R, Moore, D, Alumkal, J. J, Dymond, A, Dickinson, P. A, Ranson, M, Clack, G, De Bono, J, Elliott, T

Volltext

Abstract LB-66: Results of two phase I multicenter trials of AZD5363, an inhibitor of AKT1, 2 and 3: Biomarker and early clinical evaluation in Western and Japanese patients with a... von Banerji, Udai, Ranson, Malcolm, Schellens, Jan HM, Esaki, Taito, Dean, Emma, Zivi, Andrea, van der Noll, Ruud, Stockman, Paul K., Marotti, Marcelo, Garrett, Michelle D., Davies, Barry R., Elvin, Paul, Hastie, Andrew, Lawrence, Peter, Cheung, SY Amy, Stephens, Christine, Tamura, Kenji

Volltext

Variable neural adaptive robust controllers for uncertain systems von Lee, Yonggon, Hui, Stefen, Zivi, Edwin, Żak, Stanislaw H.

Volltext

An evaluation of blood mRNA expression array signatures derived from unsupervised analyses in the identification of prostate cancers with poor outcome von Olmos, D., Clark, J., Brewer, D., Barwell, L., Attard, G., Reid, A. H., Sandhu, S. K., Zivi, A., Bianchini, D., Babu Oomen, N., Thompson, E., Molife, L. R., Kaye, S. B., Parker, C., Cooper, C., Jones, R. J., De Bono, J. S.

Volltext

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? von Mezynski, J, Pezaro, C, Bianchini, D, Zivi, A, Sandhu, S, Thompson, E, Hunt, J, Sheridan, E, Baikady, B, Sarvadikar, A, Maier, G, Reid, A H M, Mulick Cassidy, A, Olmos, D, Attard, G, de Bono, J

Volltext